Mirikizumab — Drug Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

8 Recruiting

5 Completed trials

4 Sponsors

21 Countries

Phase III

Phase II

Phase IV

Phase III: 8 Phase II: 2 Phase IV: 4

Oversight events:

6 temporary halts 1 corrective measure across 2 trials

View oversight register →

Indications tested

Colitis ulcerative 2 Crohn´s disease 2 Crohn's disease 2

Sponsors using this IMP

Eli Lilly & Co. 11 Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif 1 Universitaetsklinikum Schleswig-Holstein AöR 1 UZ Leuven 1

All trials

14 total

A study to measure mirikizumab levels in breast milk of lactating participants receiving mirikizumab therapeutically for an approved indicat… Pending

2025-522362-78-00 Phase IV 5 countries Eli Lilly & Co.
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe… Recruiting

2024-520209-38-00 Phase III 15 countries Eli Lilly & Co.
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w… Recruiting

2023-507853-13-00 Phase II 14 countries Eli Lilly & Co.
Efficacy of MIrikizumab to achieve traNsmural healing in patiENTs with Crohn’s Disease : EMINENT CD Recruiting

2025-521889-95-00 Phase IV 1 country Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study Recruiting

2025-522338-30-00 Phase II 9 countries Eli Lilly & Co.
Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed moderate-to-severe … Recruiting

2025-522585-72-00 Phase IV 1 country Universitaetsklinikum Schleswig-Holstein AöR
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight:… Recruiting

2024-520210-21-00 Phase III 15 countries Eli Lilly & Co.
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants with Ulcerative Colitis or Crohn’s Disease (SHINE-ON) Recruiting

2023-506239-14-00 Phase III 10 countries Eli Lilly & Co.
Prevention of postoperative endoscopic disease recurrence in Crohn’s disease: a multicentric study that compares the systematic start of bio… Recruiting

2022-500311-39-00 Phase IV 2 countries UZ Leuven
A Study of Mirikizumab (LY3074828) in Pediatric Participants with Crohn’s Disease (AMAY) Ended

2024-511472-32-00 Phase III 9 countries Eli Lilly & Co.
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended

2022-502841-91-00 Phase III 14 countries Eli Lilly & Co.
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Phase III 14 countries Eli Lilly & Co.
A Study to Investigate Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moder… Ended

2022-502183-20-00 Phase III 7 countries Eli Lilly & Co.
A Study to Investigate Bowel Urgency in Adults with Moderately to Severely Active Ulcerative Colitis Treated with Mirikizumab Ended

2022-502393-16-00 Phase III 9 countries Eli Lilly & Co.

Showing 1–14 of 14 trials

← All drugs A–Z